[go: up one dir, main page]

MXPA05006663A - Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos. - Google Patents

Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos.

Info

Publication number
MXPA05006663A
MXPA05006663A MXPA05006663A MXPA05006663A MXPA05006663A MX PA05006663 A MXPA05006663 A MX PA05006663A MX PA05006663 A MXPA05006663 A MX PA05006663A MX PA05006663 A MXPA05006663 A MX PA05006663A MX PA05006663 A MXPA05006663 A MX PA05006663A
Authority
MX
Mexico
Prior art keywords
combination
agents
beta receptor
lymphotoxin beta
lymphotoxin
Prior art date
Application number
MXPA05006663A
Other languages
English (en)
Inventor
Lepage Doreen
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of MXPA05006663A publication Critical patent/MXPA05006663A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a terapias de combinacion que incluyen una composicion que activa la senalizacion del receptor linfotoxina beta en combinacion con uno u otros mas agentes quimioterapeuticos, asi como tambien metodos terapeuticos y metodos de seleccion para identificar agentes que en combinacion con un agente agonista del receptor linfotoxina beta, tienen un efecto supra-aditivo en la inhibicion de tumor.
MXPA05006663A 2002-12-20 2003-12-22 Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos. MXPA05006663A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43518502P 2002-12-20 2002-12-20
PCT/US2003/041243 WO2004058183A2 (en) 2002-12-20 2003-12-22 Lymphotoxin beta receptor agents in combination with chemotherapeutic agents

Publications (1)

Publication Number Publication Date
MXPA05006663A true MXPA05006663A (es) 2005-09-30

Family

ID=32682180

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006663A MXPA05006663A (es) 2002-12-20 2003-12-22 Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos.

Country Status (16)

Country Link
US (1) US20060134102A1 (es)
EP (1) EP1585547A4 (es)
JP (1) JP2006513225A (es)
KR (1) KR20050094819A (es)
CN (1) CN1753692A (es)
AU (1) AU2003303339A1 (es)
BR (1) BR0317573A (es)
CA (1) CA2509495A1 (es)
EA (1) EA200501019A1 (es)
IS (1) IS7900A (es)
MX (1) MXPA05006663A (es)
NO (1) NO20053529L (es)
PL (1) PL377611A1 (es)
RS (1) RS20050481A (es)
WO (1) WO2004058183A2 (es)
ZA (1) ZA200505543B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
SK5672003A3 (en) * 2000-10-13 2003-10-07 Biogen Inc Humanized anti-LT-beta-R antibodies
NZ537965A (en) * 2002-07-01 2008-04-30 Biogen Idec Inc Humanized anti-lymphotoxin beta receptor antibodies
WO2004003144A2 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
CN100473664C (zh) * 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途
CA2529945A1 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
WO2005092927A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
EP2040751A2 (en) * 2006-06-15 2009-04-01 Biogen Idec MA Inc. Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents
PE20080980A1 (es) 2006-10-12 2008-09-02 Genentech Inc Anticuerpos anti-linfotoxina alfa
CA2666934A1 (en) * 2006-10-20 2008-04-24 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP2175884B8 (en) * 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
EP3359168A4 (en) 2015-10-06 2019-08-07 Regents of the University of Minnesota THERAPEUTIC COMPOUNDS AND METHOD
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
WO2019238966A1 (en) * 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
CN120535653A (zh) 2018-10-19 2025-08-26 明尼苏达大学董事会 Nk接合子分子及其使用方法
CA3164226A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
CN117327174A (zh) * 2022-06-24 2024-01-02 广东菲鹏制药股份有限公司 抗新型冠状病毒人源化多价结合蛋白及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
DE69632681T2 (de) * 1995-01-26 2005-06-09 Biogen, Inc., Cambridge Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
EE05213B1 (et) * 1996-10-25 2009-10-15 Biogen, Incorporated Lmfotoksiin- β retseptori (LT- β-R) blokeeriva agensi kasutamine ja LT- β-R-i blokeerivat agensit ning CD40L-i blokeerivat agensit sisaldav farmatseutiline kompositsioon
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
SK5672003A3 (en) * 2000-10-13 2003-10-07 Biogen Inc Humanized anti-LT-beta-R antibodies
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
NZ537965A (en) * 2002-07-01 2008-04-30 Biogen Idec Inc Humanized anti-lymphotoxin beta receptor antibodies
CN100473664C (zh) * 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
WO2005092927A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof

Also Published As

Publication number Publication date
BR0317573A (pt) 2005-11-22
EA200501019A1 (ru) 2006-06-30
NO20053529L (no) 2005-09-20
KR20050094819A (ko) 2005-09-28
AU2003303339A1 (en) 2004-07-22
US20060134102A1 (en) 2006-06-22
WO2004058183A3 (en) 2004-12-09
EP1585547A4 (en) 2006-10-25
PL377611A1 (pl) 2006-02-06
CN1753692A (zh) 2006-03-29
WO2004058183A2 (en) 2004-07-15
RS20050481A (sr) 2007-08-03
CA2509495A1 (en) 2004-07-15
ZA200505543B (en) 2006-12-27
IS7900A (is) 2005-06-20
EP1585547A2 (en) 2005-10-19
JP2006513225A (ja) 2006-04-20
NO20053529D0 (no) 2005-07-19

Similar Documents

Publication Publication Date Title
MXPA05006663A (es) Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos.
EP1576179A4 (en) METHODS AND COMPOSITIONS INDUCING APOPTOSIS OF CANCER CELLS
EP1487436A4 (en) POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
SG147294A1 (en) Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy.
WO2005000351A3 (en) Combination therapy for b cell disorders
WO2007146414A3 (en) Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents
TWI372628B (en) Methods of modulating cytokine activity; related reagents
MX2008008340A (es) Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3.
GT200000053A (es) Moduladores del receptor glucocorticoide.
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
WO2003075841A3 (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
WO2002000617A3 (en) Selective androgen receptor modulators and methods for their identification, design and use
WO2006058236A3 (en) Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
IL182983A0 (en) 4-hydroxybenzomorphans
WO2004052348A3 (en) Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
FR13C0062I1 (es)
IN2014DN05011A (es)
CR9415A (es) Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib
EP2258381A3 (en) Ghrelin analogs
TW200531679A (en) Methods of modulating cytokine activity; related reagents
WO2004009609A3 (en) Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
WO2001038352A3 (en) Methods of inhibiting metastasis
MY133625A (en) Peptide deformylase inhibitors
AU2003258287A8 (en) Screening methods for cognitive enhancers

Legal Events

Date Code Title Description
FA Abandonment or withdrawal